

## Keytruda® (pembrolizumab) – Expanded indication

- On April 11, 2019, the FDA approved Merck's <u>Keytruda (pembrolizumab)</u>, as a single agent, for the
  first-line treatment of patients with stage III non-small cell lung cancer (NSCLC), who are not
  candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose
  tumors express PD-L1 (Tumor Proportion Score [TPS] ≥ 1%) as determined by an FDA-approved
  test, with no EGFR or ALK genomic tumor aberrations.
  - Keytruda was previously approved as a single agent, for the first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%), with no EGFR or ALK genomic tumor aberrations.
- Keytruda is also indicated for head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient solid tumors or colorectal cancer, gastric cancer, cervical cancer, hepatocellular cancer, and Merkel cell carcinoma.
- The expanded indication for Keytruda was based on data from KEYNOTE-042, an open-label study
  in 1,274 patients with stage III NSCLC, who were not candidates for surgical resection or definitive
  chemoradiation, or metastatic NSCLC, whose tumors expressed PD-L1 (TPS ≥ 1%). Patients were
  randomized to receive Keytruda or investigator's choice of a platinum-containing chemotherapy
  regimen. The main efficacy outcome measure was overall survival (OS).
  - In the overall population (patients with TPS  $\geq$  1%), median OS was 16.7 months (95% CI: 13.9, 19.7) with Keytruda vs. 12.1 months (11.3, 13.3) with chemotherapy (Hazard Ratio [HR] 0.81; 95% CI: 0.71, 0.93; p = 0.0036).
  - Keytruda also demonstrated a statistically significant improvement in OS in the subgroup of patients with TPS ≥ 50% NSCLC and the subgroup of patients with TPS ≥ 20% NSCLC.
- The recommended dose of Keytruda for NSCLC is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
- Refer to the Keytruda drug label for dosing for all other indications.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.